Dyax, ICOS to discover therapeutic antibodies

By Elaine Rigoli

Tampa, Fla., May 22 - Dyax Corp. granted a non-exclusive license to its proprietary phage display libraries to ICOS Corp. for the discovery and development of therapeutic antibodies.

Under the agreement, Dyax receives technology license fees from ICOS as well as clinical milestone payments and royalties on net sales of any products that may result from ICOS's use of the Dyax libraries, according to a news release.

The agreement provides ICOS with a license to Dyax's antibody phage display technology and patent rights as well as sublicenses to relevant third-party antibody phage display patents that may be used with Dyax's technology, the release said.

Located in Cambridge, Mass., Dyax develops biotherapeutics for unmet medical needs, with an emphasis on cancer and inflammatory indications.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.